Immunomodulatory actions of xanthenone anticancer agents

BioDrugs

Volumn 8, Issue 2, 1997, Pages 119-127

  Baguley, Bruce C ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; XANTHENE DERIVATIVE; XANTHONE 4 ACETIC ACID;

CYTOTOXICITY; DRUG ACTIVITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; NATURAL KILLER CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REVIEW;

EID: 0030875686     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708020-00005     Document Type: Review

References (63)

1. Brouckaert PGG, Fiers W, Lejeune FJ. Coley's vaccine and TNF therapy [letter]. Nature 1992; 358: 630
2. Nakanishi M, Takanore O, Tsuruda M, et al. Studies on anti-inflammatory agents. XXXI. Studies on the synthesis and anti-inflammatory activity of xanthenyl- and benzopyranopyridylacetic acid derivatives. Yakugaku Zasshi 1976; 96: 99-109
3. Rewcastle GW, Atwell GJ, Palmer BD, et al. Potential antitumor agents. 62. Structure activity relationships for tricyclic compounds related to the colon tumor active drug 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 1991; 34: 491-6
4. Atassi G, Briet P, Berthelon J-J, et al. Synthesis and antitumor activity of some 8-substituted 4-oxo-4H-1-benzopyrans. Eur J Med Chem 1985; 5: 393-402
5. Plowman J, Narayanan VL, Dykes D, et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 1986; 70: 631-8
6. Finlay GJ, Smith GP, Fray LM, et al. Effect of flavone acetic acid (NSC 347512) on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst 1988; 80: 241-5
7. Smith GP, Calveley SB, Smith MJ, et al. Flavone acetic acid (NSC 347512) induces haemorrhagic necrosis of mouse colon 26 and 38 tumours. Eur J Cancer Clin Oncol 1987; 23: 1209-12
8. Baguley BC, Calveley SB, Crowe KK, et al. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on Colon 38 tumors in mice. Eur J Cancer Clin Oncol 1989; 25: 263-9
9. Atwell GJ, Rewcastle GW, Baguley BC, et al. Potential antitumor agents. 60. Relationships between structure and in vivo colon 38 activity for 5-substituted xanthenone-4-acetic acids. J Med Chem 1990; 33: 1375-9
10. Rewcastle GW, Atwell GJ, Baguley BC, et al. Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the Colon 38 tumor in vivo. J Med Chem 1989; 32: 793-9
11. Rewcastle GW, Atwell GJ, Zhuang L, et al. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 1991; 34: 217-22
12. Rewcastle GW, Atwell GJ, Baguley BC, et al. Potential antitumor agents. 63. Structure-activity relationships for side-chain analogues of the Colon-38 active agent 9-oxo-9H-xanthene-4-acetic acid. J Med Chem 1991; 34: 2864-70
13. Kerr DJ, Kaye SB. Flavone acetic acid-preclinical and clinical activity. Eur J Cancer Clin Oncol 1989; 25: 1271-2
14. de Forni M, Chabot GG, Armand JP, et al. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization. Cancer Chemother Pharmacol 1995; 35: 219-24
15. Holmund JT, Kopp WC, Wiltrout RH, et al. A phase I clinical trial of flavone-8-acetic acid in combination with interleukin 2. J Natl Cancer Inst 1995; 87: 134-6
16. Ching LM, Joseph WR, Crosier KE, et al. Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 1994; 54: 870-2
17. Zwi LJ, Baguley BC, Gavin JB, et al. The morphological effects of the anti-tumour agents flavone acetic acid and 5,6-dimethylxanthenone acetic acid on the colon 38 mouse tumour. Pathology 1994; 26: 161-9
18. Futami H, Eader LA, Back TT, et al. Cytokine induction and therapeutic synergy with interleukin-2 against murine renal and colon cancers by xanthenone-4-acetic acid derivatives. J Immunother 1992; 12: 247-55
19. Philpott M, Baguley BC, Ching L-M. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1995; 36: 143-8
20. Ching L-M, Xu Z-F, Gummer BH, et al. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 72: 339-43
21. Ching L-M, Baguley BC. Induction of natural killer cell activity by the antitumour compound flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 1987; 23: 1047-50
22. Wiltrout RH, Boyd MR, Back TC, et al. Flavone-8-acetic acid augments systemic natural killer cell activity and synergizes with IL-2 for treatment of murine renal cancer. J Immunol 1988; 140: 3261-5
23. Ching L-M, Joseph WR, Zhuang L, et al. Induction of natural killer activity by xanthenone analogues of flavone acetic acid: relation with antitumour activity. Eur J Cancer 1991; 27: 79-83
24. Hornung RL, Young HA, Urba WJ, et al. Immunomodulation of natural killer cell activity by flavone acetic acid, occurrence via induction of interferon alpha/beta. J Natl Cancer Inst 1988; 80: 1226-31
25. Dalton DK, Pittsmeek S, Keshav S, et al. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 1993; 259: 1739-42
26. Ching L-M, McKeage M, Joseph WR, et al. Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid. Cancer Chemother Pharmacol 1991; 28: 414-9
27. Kizaki H, Nakada S, Ohnishi Y, et al. Tumour necrosis factor-alpha enhances cAMP-induced programmed cell death in mouse thymocytes. Cytokine 1993; 5: 342-7
28. Ching L-M, Baguley BC. Reduction of cytotoxic effector cell activity in Colon 38 tumours following treatment with flavone acetic acid. Eur J Cancer Clin Oncol 1989; 25: 1061-5
29. Pratesi G, Rodolfo M, Rovetta G, et al. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur J Cancer 1990; 26: 1079-83
30. Bibby MC, Phillips RM, Double JA, et al. Anti-tumour activity of flavone acetic acid (NSC-347512) in mice - influence of immune status. Br J Cancer 1991; 63: 57-62
31. Bibby MC, Double JA, Phillips RM, et al. Flavone acetic acid - is vascular shutdown the crucial mechanism of action? Int J Radiat Biol 1991; 60: 395-9
32. Ching LM, Joseph WR, Baguley BC. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 1992; 66: 128-30
33. Laws AL, Matthew AM, Double JA, et al. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995; 71: 1204-9
34. Evelhoch JL, Bissery M-C, Chabot GG, et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 1988; 48: 4749-55
35. Bibby MC, Double JA, Loadman PM, et al. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 1989; 81: 216-20
36. Zwi LJ, Baguley BC, Gavin JB, et al. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J Natl Cancer Inst 1989; 81: 1005-13
37. Zwi LJ, Baguley BC, Gavin JB, et al. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol Res 1994; 6: 79-85
38. Mackay F, Loetscher H, Stueber D, et al. Tumor necrosis factor-alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-r55. J Exp Med 1993; 177: 1277-86
39. Thomsen LL, Ching LM, Baguley BC. Evidence for the production of nitric oxide by activated macrophages treated with the antitumor agents flavone-8-acetic acid and xanthenone-4-acetic acid. Cancer Res 1990; 50: 6966-70
40. Baguley BC, Zhuang L, Kestell P. Increased plasma serotonin following treatment with flavone acetic acid, dimethylxanthenone acetic acid, vinblastine and colchicine: relation to vascular effect [abstract]. Proc Am Assoc Cancer Res 1995; 36: 349
41. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298: 249-58
42. Baguley BC, Cole G, Thomsen LL, et al. Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1993; 33: 77-81
43. Ching L-M, Baguley BC. Enhancement of in vitro toxicity of mouse peritoneal exudate cells by flavone acetic acid (NSC 347512). Eur J Cancer Clin Oncol 1988; 24: 1521-5
44. Ching L-M, Finlay GJ, Joseph WR, et al. In vitro methods for screening agents with an indirect mechanism of antitumour activity: xanthenone analogues of flavone acetic acid. Eur J Cancer 1991; 27: 1684-9
45. Ching L-M, Joseph WP, Baguley BC. Stimulation of macrophage tumoricidal activity by 5,6-dimethylxanthenone-4-acetic acid, a potent analogue of the antitumor agent flavone-8-acetic acid. Biochem Pharmacol 1992; 44: 192-5
46. Perera PY, Barber SA, Ching LM, et al. Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages - dissection of signaling pathways leading to gene induction and tyrosine phosphorylation. J Immunol 1994; 153: 4684-93
47. Mace KF, Hornung RL, Wiltrout RH, et al. Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer. Cancer Res 1990; 50: 1742-7
48. Ching LM, Joseph WR, Zhuang L, et al. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother Pharmacol 1994; 35: 153-60
49. Thomsen LL, Baguley BC, Ching LM, et al. Modulation of superoxide production from murine macrophages by the antitumour agent flavone acetic acid and xanthenone acetic acid analogues. Biochem Pharmacol 1992; 43: 386-9
50. Rewcastle GW, Kestell P, Baguley BC, et al. Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 1990; 82: 528-9
51. Kestell P, McKeage MJ, Baguley BC. Determination of xanthenone-4-acetic acid in mouse plasma by high-performance liquid chromatography. J Chromatogr 1991; 564: 315-21
52. Kestell P, Rewcastle GW, Baguley BC. Disposition of the novel antitumour agent xanthenone-4-acetic acid in the mouse: identification of metabolites and routes of elimination. Xenobiotica 1994; 24: 635-47
53. Webster LK, Ellis AG, Kestell P, et al. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab Dispos 1995; 23: 363-8
54. McKeage MJ, Kestell P, Denny WA, et al. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol 1991; 28: 409-13
55. Thomsen LL, Ching LM, Zhuang L, et al. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res 1991; 51: 77-81
56. Zwi LJ, Baguley BC, Gavin JB, et al. Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid. Br J Cancer 1990; 62: 932-4
57. Ferrara JL. Cytokine inhibitors and graft-versus-host disease. Ann NY Acad Sci 1995; 770: 227-36
58. Mattila P, Majuri ML, Mattila PS, et al. TNF alpha-induced expression of endothelial adhesion molecules, ICAM-1 and VCAM-1, is linked to protein kinase-C activation. Scand J Immunol 1992; 36: 159-65
59. Argenbright LW, Barton RW. Interactions of leukocyte integrins with intercellular adhesion molecule 1 in the production of inflammatory vascular injury in vivo: the Shwartzman reaction revisited. J Clin Invest 1992; 89: 259-72
60. Zwi LJ, Baguley BC, Gavin JB, et al. The use of vascularised spheroids to investigate the action of flavone acetic acid on tumour blood vessels. Br J Cancer 1990; 62: 231-7
61. Murray JC, Clauss M, Denekamp J, et al. Selective induction of endothelial cell tissue factor in the presence of a tumour-derived mediator - a potential mechanism of flavone acetic acid action in tumour vasculature. Int J Cancer 1991; 49: 254-9
62. Watts ME, Murray JC, Smith KA, et al. Flavone acetic acid as a modifier of endothelial cell function. Int J Radiat Oncol Biol Phys 1992; 22: 431-5
63. Sen R, Baltimore D. Inducibility of kappa immunoglobulin enhancer-binding protein NF-kappa B by a posttranslational mechanism. Cell 1986; 47: 921-8